Form 4: Acrivon Therapeutics Chief Legal Officer Reports Stock Transaction
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, reports the disposal of 184 common stock shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On August 14, 2024, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., reported a transaction involving the company's common stock.
- A total of 184 shares were disposed of at a price of $7.02 per share to satisfy tax withholding requirements.
- Following the transaction, Miller directly owns 38,967 shares of Acrivon Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a routine transaction related to tax obligations, so it's neutral in sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC for corporate insiders, providing transparency into their transactions in the company's stock. This is a routine transaction related to tax obligations.
Key Dates
| Date | Description |
|---|---|
| 08/14/2024 | Date of stock transaction (disposal of shares). |
| 08/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.